This review assessed the use of dipyridamole, with or without aspirin, for preventing stroke in patients with previous ischaemic cerebrovascular disease. The authors concluded that dipyridamole, with or without aspirin, reduced stroke recurrence in this population. The review appeared to support the authors' conclusions, but the incomplete reporting of review methods makes it difficult to confirm the robustness of the conclusions.
randomisation, concealment of allocation, completeness of follow-up, and blinding of the outcome assessment. Trials satisfying at least three of the criteria listed were considered to be of a high quality. The authors sought to clarify differences between their analysis of the data according to methods used in trial publications and published results. The authors did not state how the quality of the primary studies was assessed, or how many reviewers carried out the quality assessment.
Data extraction
Trial investigators were contacted to provide IPD for their trial. The data requested included: demographics, clinical presentation, treatment assignment, treatment findings and outcome at the end of the trial. Data were re-coded by the authors and merged into a single datset. Comparisons by treatment group included: dipyridamole versus control or placebo; combined aspirin and dipyridamole versus control or placebo; combined aspirin and dipyridamole versus aspirin; and combined aspirin and dipyridalmole versus dipyridamole.
Methods of synthesis
How were the studies combined? For each outcome, a pooled odds ratio (OR) with associated 95% confidence interval (CI) was calculated by intentionto-treat. A random-effects model was used to account for heterogeneity between trial results and a fixed-effect model for treatment assignment. Regression methods were used to adjust for age, gender, qualifying event and history of hypertension. Egger's test for asymmetry (based on the OR for stroke recurrence) was used to assess the potential for publication bias.
How were differences between studies investigated?
A subgroup analysis was used to examine the effect on stroke recurrence of prognostic factors (age, stroke as a qualifying event and history of hypertension). A sensitivity analysis was used to assess the influence on total stroke of the formulation of dipyridamole (conventional or modified release), risk of recurrence, each trial in turn, inclusion of a non-randomised clinical trial, and the inclusion of tabular data from the two studies with unobtainable IPD.
Results of the review
Seven trials (n=11,509) were eligible; IPD from 5 RCTs were included in the meta-analysis (n=11,290). Six RCTs were considered to be of a high quality.
Vascular events: After adjusting for age, gender, and qualifying event, recurrent stroke was reduced by dipyridamole compared with control or placebo (OR 0.82, 95% CI: 0.68, 1.00). Similarly, recurrent stroke was statistically significantly reduced by dipyridamole combined with aspirin compared with aspirin alone (OR 0.78, 95% CI: 0.65, 0.93), dipyridamole alone (OR 0.74, 95% CI: 0.60, 0.90), or control (OR 0.61, 95% CI: 0.51, 0.71). When data from the largest trial were excluded (accounting for 57% of the data), the comparison of combined aspirin and dipyridamole with control remained statistically significant (OR 0.63, 95% CI: 0.48, 0.82), but demonstrated a non-statistically significant trend (OR 0.88, 95% CI: 0.64, 1.19) compared with aspirin alone. Similar findings were demonstrated for nonfatal stroke. The composite outcome of nonfatal stroke, nonfatal MI and vascular death was statistically significantly reduced by dipyridamole combined with aspirin when compared with aspirin alone (OR 0.84, 95% CI: 0.72, 0.97), dipyridamole alone (OR 0.76, 95% CI: 0.64, 0.90), or control or placebo (OR 0.66, 95% CI: 0.57, 0.75). Type of treatment did not statistically reduce the odds of vascular death in any group.
Blood pressure: Dipyridamole, with or without aspirin, lowered blood pressure by 1.1/0.9 mmHg (0.7/0.6%; P=0.037, P>0.001; based on 2 RCTs). However, the reduction in stroke seen with dipyridamole was not statistically significantly associated with the fall in blood pressure (P=0.37).
Drop-out rate and adverse events: The drop-out rate was higher with dipyridamole alone (29.3%) and dipyridamole plus aspirin (30.8%) compared with aspirin alone (24%) or control (23.4%). Headaches were more common with dipyridamole alone (37.2%) and aspirin alone (33.1%) compared with aspirin plus dipyridamole (26.7%) or control (22.8%). Bleeding was greatest in patients receiving aspirin alone (8.2%) or aspirin plus dipyridamole (8.1%) compared with dipyridamole alone (4.7%) or control (4.2%). 
